PRACTITIONER INFORMATION

MAINTRAC CASE STUDIES

CASE STUDY 2020/11 TRIPLE NEGATIVE BREAST CANCER: The detection of tumour spheres to assist in monitoring high risk patients

Case History:
Female aged 62 years.

cT2, N0, M0 TNBC with Ki67>90% in 2018.

Patient rejected recommended adjuvant therapy, patient chose (read more)

CASE STUDY 2020/10 PROSTATE CANCER: The detection of tumour spheres to assist in monitoring high risk patients

Case History:
Male, diagnosed with local Prostate Cancer in 2009 at the age of 61. He had Gleason score of 7. Patient did not receive surgery and elected for a "watch and wait" plus complementary therapy approach.

PSA is low but rising intermittently. Scans are (read more)

CASE STUDY 2020/9 Periodic CTC Counts as monitor for SCC

Case History:
Patient is a 72 year old female with SCC left jaw. She has had extensive surgery, radiotherapy according to guidelines, 2 years of recurrent infections, reconstruction and remission.

Although SCC is a cancer which carries a low risk of distant metastases, this patient's histology demonstrated (read more)

CASE STUDY 2020/8 prostate cancer monitoring

Introduction: 
Patient is a 73 year old male initially diagnosed with Prostate Cancer in 2012, Gleason 7 with intraprostatic tumour. Patient received local radiotherapy as treatment. Hormone disruptive therapy commenced in 2014 and one year later (read more)

CASE STUDY 2020/7 Is it time to consider a change in treatment?

Case History:
Patient is a 35 year old male with Stage 2 Colon Cancer, T2N0M0, diagnosed in 2016. He had surgery and adjuvant therapy in 2016 and is overall healthy and focused on prevention.

CTC counts have been used as a monitor for treatment effectiveness and to measure (read more)

CASE STUDY 2020/6 MONITORING BREAST CANCER WITH CTCS

Case History:
Female aged 50 diagnosed with stage 2 Breast Cancer in 2016:
     • ER+
     • aggressive DCIS plus Luminal B Mastectomy
     • delayed adjuvant therapy with chemo and radiation therapy
     • SERM (Zoladex) since 2018

Patient initially rejected guideline therapy. (read more)

CASE STUDY 2020/5 Rising ctcs in patient with prostate cancer

Case History:
72 year old male diagnosed with low grade prostate cancer in 2011; PSA was low and steady. In 2017 he was diagnosed with SCC (squamous cell carcinoma) on the scalp, possibly invasive. 

Otherwise healthy, he wants to prevent recurrence/progression of disease with (read more)

CASE STUDY 2020/4 Ki67 as an additional marker on CTCs

Introduction:  Ki67 is a nuclear protein associated with cell proliferation. It is present during all active phases of the growth cycle, but is absent in resting (quiescent) cells. Ki67 is identified with the IHC method. The presence of Ki67 protein on CTCs (circulating tumour cells) indicates the percentage of CTCs in the active growth phase of the cell cycle. Higher amounts are associated with an increased risk of progression or recurrence.

CTCs and Ki67 together, provide a very useful tool in monitoring treatment effectiveness as well as (read more)

CASE STUDY 2020/3 Treatment Selection for Metastatic Cancer

Case History:
Patient is a 65 year old female diagnosed with metastatic NSCLC (non small cell lung cancer) in 2018. She received guideline therapies with partial response. Patient wishes to include adjunctive IV therapy.

Substances to consider for IV therapy:
     • Vitamin C
     • Curcumin
     • Resveratrol

Testing CTCs (circulating tumour cells) with the Maintrac® system provides (read more)

CASE STUDY 2020/2 CTC MONITORING IN TNBC

Case History:
44 year old female diagnosed with Triple Negative Breast Cancer (TNBC) in 2014. Treatment based on standard guidelines, surgery and adjuvant therapy with chemotherapy and local radiation. Ongoing preventative management.

Low risk patient with TNBC, which carries HIGH (read more)

CASE STUDY 2020/1 DETECTION OF CANCER STEM CELLS

Case History:
A 60 year old female diagnosed in 2017 with ER+ Breast Cancer with bone metastases.
Treatment consisted of:
     • surgical removal of the breast cancer tumour
     • radiation therapy to bone metastases
     • patient rejected adjuvant chemotherapy
     • hormonal therapy

In addition, active and interventional complementary treatments including (read more)